PER — Percheron Therapeutics Share Price
0.000.00%
Last trade - 00:00- AU$61.31m
- AU$44.13m
- AU$0.38m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.73 | ||
| Price to Tang. Book | 3.73 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 98.17 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -70.75% | ||
| Return on Equity | -66.78% | ||
| Operating Margin | -1864.16% | ||
Financial Summary
| Year End 30th Jun | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 0.07 | 0.03 | 0 | 0.03 | 0.38 | 2.27 | 2.3 | 72.03% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Percheron Therapeutics Limited, formerly Antisense Therapeutics Limited, is a biotechnology company. The Company is engaged in developing and commercializing antisense pharmaceuticals for large unmet markets in rare diseases. The Company’s products include ATL1102 for Duchenne muscular dystrophy (DMD), ATL1103 for Acromegaly, and ATL1102 for Multiple Sclerosis (MS). ATL1102, is an antisense inhibitor targeting very late antigen 4 (VLA-4), an immune cell molecule. ATL1103 is a second-generation antisense drug designed to block growth hormone receptor (GHr) expression thereby reducing levels of the hormone insulin-like growth factor-I (IGF-I) in the blood and is a potential treatment for diseases associated with excessive growth hormone action. By inhibiting GHr production, ATL1103 in turn reduces IGF-I levels in the blood (serum). The Company is conducting a Phase II clinical trial of ATL1102 in DMD patients.
Directors
- Robert Moses NEC
- Phillip Hains CFO
- Mark Diamond MDR
- Nuket Desem OTH
- George Tachas OTH
- Alicia Mellors SEC
- Gary Pace NED (73)
- Ben Price NED
- Last Annual
- June 30th, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- November 13th, 2000
- Public Since
- December 20th, 2001
- No. of Shareholders
- 4,177
- No. of Employees
- 8
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Australian Stock Exchange - SEATS
- Shares in Issue
- 901,544,971
- Address
- 14 Wallace Avenue,, Toorak, MELBOURNE, 3142
- Web
- https://www.antisense.com.au/
- Phone
- +61 398278999
- Auditors
- Ernst & Young
Upcoming Events for PER
Similar to PER
Actinogen Medical
Australian Stock Exchange - SEATS
Adalta
Australian Stock Exchange - SEATS
Algorae Pharmaceuticals
Australian Stock Exchange - SEATS
Alterity Therapeutics
Australian Stock Exchange - SEATS
Amplia Therapeutics
Australian Stock Exchange - SEATS
FAQ
What is the Percheron Therapeutics share price?
As of Today at 19:16 UTC, shares in Percheron Therapeutics are trading at AU$0.07. This share price information is delayed by 15 minutes.
How has the Percheron Therapeutics share price performed this year?
Shares in Percheron Therapeutics last closed at AU$0.07 and the price had moved by -12.82% over the past 365 days. In terms of relative price strength the Percheron Therapeutics share price has underperformed the ASX All Ordinaries Index by -17.82% over the past year.
What are the analyst and broker recommendations for Percheron Therapeutics?
The overall consensus recommendation for Percheron Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Percheron Therapeutics dividend yield?
Percheron Therapeutics does not currently pay a dividend.
Does Percheron Therapeutics pay a dividend?
Percheron Therapeutics does not currently pay a dividend.
When does Percheron Therapeutics next pay dividends?
Percheron Therapeutics does not currently pay a dividend.
How do I buy Percheron Therapeutics shares?
To buy shares in Percheron Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Percheron Therapeutics?
As of the previous close price of AU$0.07, shares in Percheron Therapeutics had a market capitalisation of AU$61.31m.
Where are Percheron Therapeutics shares listed?
Here are the trading details for Percheron Therapeutics:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: PER
What kind of share is Percheron Therapeutics?
Based on an overall assessment of its quality, value and momentum Percheron Therapeutics is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Percheron Therapeutics share price forecast for 2024?
The analyst consensus target price for shares in Percheron Therapeutics is AU$0.25. That is 267.65% above the last closing price of AU$0.07.
Analysts covering Percheron Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -AU$0.02 for the next financial year.
What is the trend in the Percheron Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Percheron Therapeutics. Over the past six months, its share price has outperformed the ASX All Ordinaries Index by +1.06%.
As of the last closing price of AU$0.07, shares in Percheron Therapeutics were trading +3.97% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Percheron Therapeutics PE Ratio?
The Percheron Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at AU$0.07.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Percheron Therapeutics?
Percheron Therapeutics' management team is headed by:
- Robert Moses - NEC
- Phillip Hains - CFO
- Mark Diamond - MDR
- Nuket Desem - OTH
- George Tachas - OTH
- Alicia Mellors - SEC
- Gary Pace - NED
- Ben Price - NED